# Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis

> **NCT00390221** · PHASE2 · COMPLETED · sponsor: **Biogen** · enrollment: 621 (actual)

## Conditions studied

- Relapsing-Remitting Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** BIIB019 (Daclizumab High Yield Process)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00390221
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2011-05
- **Final completion:** 2011-08
- **Target enrollment:** 621 (ACTUAL)
- **Last updated:** 2016-07-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00390221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00390221, "Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT00390221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*